| abstract |
The present invention relates to: a chimeric antigen receptor specifically binding to HLA class II; a polynucleotide encoding a protein of the chimeric antigen receptor; a vector comprising the polynucleotide; a cell transformed with the vector; and a cell therapy product or a pharmaceutical composition for treating cancer, comprising the cell as an active ingredient. The chimeric antigen receptor according to the present invention comprises extracellular domains (1 to 4) of LAG-3 that specifically binds to HLA class II (HLA-DP, HLA-DQ, HLA-DR). Therefore, in the case of cytotoxic T cells or natural killer cells that are transformed with a vector that can overexpress the chimeric antigen receptor, the cells have cytotoxicity specifically to carcinoma expressing HLA class II (HLA-DP, HLA-DQ, HLA-DR), and thus the cells may be usefully utilized as immune cell therapeutic agents for cancer treatment. |